NEUTROPENIC SEPSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

• Research type

  Research Study

• Full title

  A RETROSPECTIVE CHART REVIEW TO DESCRIBE THE RATE OF NEUTROPENIC SEPSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH SINGLE-AGENT DOCETAXEL AND ASSOCIATED RESOURCE USE IN THE UK

• IRAS ID

  198232

• Contact name

  Thomas Newsom-Davis

• Contact email

  tom.newsom-davis@chelwest.nhs.uk

• Sponsor organisation

  Roche Products Ltd

• Duration of Study in the UK

  0 years, 6 months, 30 days

• Research summary

  This is an observational, retrospective, multicentre, descriptive research study that aims to describe the rate of neutropenic sepsis (NS) in patients with relapsed non small cell lung cancer (NSCLC) treated with docetaxel. The study will take place in 5-8 secondary/tertiary centres in the UK. Centres will be selected that routinely treat patients with docetaxel for treatment of relapsed NSCLC. The study will recruit approximately 120 patients.
  This observational study will collect retrospective information relating to demographics, relevant medical history and prescribing of docetaxel for all patients.
  Retrospective data will be collected from patients’ medical records by members of the direct care team,and provided in anonymised form to research staff, therefore consent will not be sought.

• REC name

  N/A

• REC reference

  N/A